Louis Moore Bacon's BCYC Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 275,000 shares of Bicycle Therapeutics plc (BCYC) worth $1.28 M, representing 0.03% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Louis Moore Bacon has maintained this position in BCYC for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 150,000 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Bicycle Therapeutics plc (BCYC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bicycle Therapeutics plc (BCYC) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +150,000 | Add 120.00% | 275,000 | $7.08 |
| Q3 2025 | +50,000 | Add 66.67% | 125,000 | $7.74 |
| Q2 2025 | +25,000 | Add 50.00% | 75,000 | $6.95 |
| Q1 2025 | +50,000 | New Buy | 50,000 | $8.49 |
Louis Moore Bacon's Bicycle Therapeutics plc Investment FAQs
Louis Moore Bacon first purchased Bicycle Therapeutics plc (BCYC) in Q1 2025, acquiring 50,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Bicycle Therapeutics plc (BCYC) for 5 quarters since Q1 2025.
Louis Moore Bacon's largest addition to Bicycle Therapeutics plc (BCYC) was in Q4 2025, adding 275,000 shares worth $1.95 M.
According to the latest 13F filing for Q1 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 275,000 shares of Bicycle Therapeutics plc (BCYC), valued at approximately $1.28 M.
As of the Q1 2026 filing, Bicycle Therapeutics plc (BCYC) represents approximately 0.03% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Bicycle Therapeutics plc (BCYC) was 275,000 shares, as reported at the end of Q4 2025.